</head> <body class="production CliniciansBrief">
CB Partner Webinar {{webinarsregistrationpage::webinar_title}} {{webinarsregistrationpage::race_approved}} true 1 Credit Hour {{webinarsregistrationpage::hero_image}} {{webinarsregistrationpage::hero_image_self_hosted}} {{webinarsregistrationpage::hero_image_desktop_background_position}} {{webinarsregistrationpage::hero_image_mobile_background_position}} {{webinarsregistrationpage::hero_image_custom_padding}} {{webinarsregistrationpage::hero_image_custom_padding_mobile}} PetDX {{webinarsregistrationpage::supported_by}} {{webinarsregistrationpage::multiple_speakers}}

A single blood test with the ability to detect 30 different types of cancer—it may seem too good to be true, but it’s the new reality. Liquid biopsy for noninvasive, multicancer detection is now available for dogs. This webinar will provide an overview of how next-generation sequencing can be used to detect cancer-associated genomic alterations in the blood of dogs. Data from the clinical validation study of this technology in a cohort of more than 1,000 dogs will be presented, along with a review of how test results can be interpreted to help pet parents understand what a positive or negative liquid biopsy result means for their dog. The session will conclude with a series of interesting case studies demonstrating how this test is being used in clinical practice.

{{webinarsregistrationpage::inside_the_webinar_2}} {{webinarsregistrationpage::inside_the_webinar_3}} Define “liquid biopsy” and examine how next-generation sequencing can be used to identify cancer-associated genomic alterations in the blood of dogs. Review test performance metrics such as sensitivity and specificity and determine positive and negative predictive values to better understand your patient’s liquid biopsy results. Identify real-world opportunities for liquid biopsy incorporation into routine wellness examinations or as an aid in diagnosis when cancer is on the differential diagnoses list. {{webinarsregistrationpage::what_youll_learn_bullet_4}} {{webinarsregistrationpage::what_youll_learn_bullet_5}} {{webinarsregistrationpage::what_youll_learn_bullet_6}} {{webinarsregistrationpage::additional_subhead}} {{webinarsregistrationpage::additional_copy}} In adherence with RACE guidelines, CE certificates can only be distributed to individual registrants under the name used upon registration. Group viewers will not be eligible to receive multiple CE certificates.

A single blood test with the ability to detect 30 different types of cancer—it may seem too good to be true, but it’s the new reality. Liquid biopsy for noninvasive, multicancer detection is now available for dogs. This webinar will provide an overview of how next-generation sequencing can be used to detect cancer-associated genomic alterations in the blood of dogs. Data from the clinical validation study of this technology in a cohort of more than 1,000 dogs will be presented, along with a review of how test results can be interpreted to help pet parents understand what a positive or negative liquid biopsy result means for their dog. The session will conclude with a series of interesting case studies demonstrating how this test is being used in clinical practice.

What You'll Learn

A single blood test with the ability to detect 30 different types of cancer—it may seem too good to be true, but it’s the new reality. Liquid biopsy for noninvasive, multicancer detection is now available for dogs. This webinar will provide an overview of how next-generation sequencing can be used to detect cancer-associated genomic alterations in the blood of dogs. Data from the clinical validation study of this technology in a cohort of more than 1,000 dogs will be presented, along with a review of how test results can be interpreted to help pet parents understand what a positive or negative liquid biopsy result means for their dog. The session will conclude with a series of interesting case studies demonstrating how this test is being used in clinical practice.

What You'll Learn